Methotrexate in acute persistent humoral rejection: an option for graft rescue.
Humoral response emerges as an important component in acute graft rejection and a new challenge to clinicians in posttransplant care. Management of recurrent episodes and persistent activation of the humoral component of the immune system, despite the usual therapeutic approach to rejection, remains unknown. This article describes the successful use of methotrexate as an option for rescuing a graft in this worrisome situation.
Bacal
Fernando
F
Heart Failure Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil. fbacal@uol.com.br
Sodré
Gustavo L
GL
Fernandes
Daniela A
DA
Aiello
Vera D
VD
Stolf
Noedir
N
Bocchi
Edimar
E
Bellotti
Giovanni
G
D000208:Acute Disease; D000328:Adult; D000917:Antibody Formation / Q000502:physiology; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D016027:Heart Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000379:methods; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D011379:Prognosis; D014181:Transplantation Immunology; D016896:Treatment Outcome
D008727:Methotrexate